IntroductionA titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram. Furthermore, the recommended reference range disagrees with mean steady state concentrations (11–21 ng/ml) that are expected under the approved dose range (10–20 mg/day). This work systematically investigated the relationships between escitalopram dose, blood levels, clinical effects, and serotonin transporter occupancy.MethodsFollowing our previously published methodology, relevant articles were systematically searched and reviewed for escitalopram.ResultsOf 1,032 articles screened, a total of 30 studies ...
Rationale: While one of the basic axioms of pharmacology postulates that there is a relationship bet...
Background: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat pediatric anx...
This study was conducted in order to access the bioequivalence of two tablets containing escitalopra...
IntroductionA titration within a certain therapeutic reference range presupposes a relationship betw...
Introduction: A titration within a certain therapeutic reference range presupposes a relationship be...
Although the favourable characteristics of escitalopram as being the most selective serotonin reupta...
BACKGROUND: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment o...
We assessed pharmacokinetic correlates of treatment response to escitalopram using a large therapeut...
Background: For many psychotropic drugs, monitoring of drug concentrations in the blood (Therapeutic...
none5noMajor Depression Disorder (MDD) has a highly variable treatment response due to the large int...
Although the favourable characteristics of escitalopram as being the most selective serotonin reupta...
The purpose of this study was to characterize escitalopram population pharmacokinetics (PK) in patie...
The purpose of this study was to characterize escitalopram population pharmacokinetics (PK) in patie...
Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughou...
Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carl...
Rationale: While one of the basic axioms of pharmacology postulates that there is a relationship bet...
Background: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat pediatric anx...
This study was conducted in order to access the bioequivalence of two tablets containing escitalopra...
IntroductionA titration within a certain therapeutic reference range presupposes a relationship betw...
Introduction: A titration within a certain therapeutic reference range presupposes a relationship be...
Although the favourable characteristics of escitalopram as being the most selective serotonin reupta...
BACKGROUND: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment o...
We assessed pharmacokinetic correlates of treatment response to escitalopram using a large therapeut...
Background: For many psychotropic drugs, monitoring of drug concentrations in the blood (Therapeutic...
none5noMajor Depression Disorder (MDD) has a highly variable treatment response due to the large int...
Although the favourable characteristics of escitalopram as being the most selective serotonin reupta...
The purpose of this study was to characterize escitalopram population pharmacokinetics (PK) in patie...
The purpose of this study was to characterize escitalopram population pharmacokinetics (PK) in patie...
Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughou...
Bernardo Dell’Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A Carl...
Rationale: While one of the basic axioms of pharmacology postulates that there is a relationship bet...
Background: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat pediatric anx...
This study was conducted in order to access the bioequivalence of two tablets containing escitalopra...